Telmisartan and Insulin Resistance in HIV (TAILoR): protocol for a dose-ranging phase II randomised open-labelled trial of telmisartan as a strategy for the reduction of insulin resistance in HIV-positive individuals on combination antiretroviral therapy

INTRODUCTION: Telmisartan, an angiotensin receptor blocker, has beneficial effects on insulin resistance and cardiovascular health in non-HIV populations. This trial will evaluate whether telmisartan can reduce insulin resistance in HIV-positive individuals on combination antiretroviral therapy. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Pushpakom, Sudeep P, Taylor, Claire, Kolamunnage-Dona, Ruwanthi, Spowart, Catherine, Vora, Jiten, García-Fiñana, Marta, Kemp, Graham J, Whitehead, John, Jaki, Thomas, Khoo, Saye, Williamson, Paula, Pirmohamed, Munir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
HIV/AIDS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4611177/
https://www.ncbi.nlm.nih.gov/pubmed/26474943
http://dx.doi.org/10.1136/bmjopen-2015-009566

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4611177/
https://www.ncbi.nlm.nih.gov/pubmed/26474943
http://dx.doi.org/10.1136/bmjopen-2015-009566

Ejemplares similares